The objective of this study is to identify and validate metastasis protein markers in lymph collected from women with metastatic breast cancer. We will examine peripheral blood for the presence of these identified markers in order to develop a user friendly clinical test to detect metastasis and to evaluate response to therapy.
Full Title of Study: “The Comparison of Lymph Fluid and Blood From Metastatic and Non-metastatic Invasive Breast Cancer Patients for Identification of Novel Biomarkers”
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: April 2020
The goal of the study is to identify node-negative breast cancer patients who are unlikely to benefit from adjuvant chemotherapy, thus saving them from the adverse effects of unnecessary treatment. We propose to identify and validate protein markers that can determine breast cancer recurrence and metastasis, based on an approach our group has recently found highly promising for biomarker discovery. The objective of our research is to identify and validate metastasis protein markers in lymph collected from vessels exiting from the primary tumor and prior to their entry into sentinel lymph node in women with metastatic breast cancer. Realizing that this novel procedure cannot be adopted for routine clinical use, we will examine the peripheral blood for the presence of these identified markers in order to develop a user friendly clinical test to detect metastasis and to evaluate response to therapy.
Clinical Trial Outcome Measures
- Identification and Validation of Metastasis Protein Markers
- Time Frame: Every 6 mo. for 5 years
- Lymph fluid collected at surgery; blood collected at surgery and then every 6 months for 5 years.
Participating in This Clinical Trial
- Women, age greater than or equal to 18, with histologically and/or cytologically confirmed diagnosis of adenocarcinoma of the breast with metastatic (node positive) and/or non-metastatic (node negative) breast cancer. – No prior chemotherapy treatment. – Women, age greater than or equal to 18, with carcinoma in situ that opted for mastectomy. – Able to provide informed consent and HIPAA authorization. Exclusion Criteria:
- Hormone therapy in the past six months. Birth control pill use is allowed. – History of radiation therapy to the chest. – Previous or current use of aromatase inhibitor (AI) or Selective Estrogen Receptor Modulator (SERM) medication. – History of chemotherapy for breast or other cancers. – Pregnant or breast-feeding.
Gender Eligibility: Female
Minimum Age: 18 Years
Maximum Age: 80 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Indiana University
- Provider of Information About this Clinical Study
- Overall Official(s)
- Monet Bowling, MD, Principal Investigator, Indiana University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.